Development of Triterpene as a New Class of HCV Entry Inhibitors

• 作 者: FeiYu;QiWang;SulongXiao;YiyunPeng;YongxiangZheng;ChuanlingZhang;DianSun;LiheZhang;DeminZhou;
• 机 构: State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking Univer
• 出 处: 第九届IUPAC化学生物学国际研讨会暨第八届世界华人药物化学研讨会
• 发表日期: 2012年期

　　Hepatitis C Virus(HCV) infection continues to be a major global health problem,which can cause chronic hepatitis,liver cirrhosis,and hepatocellular carcinoma.1 Consequently,HCV-induced disease is the leading indication for liver transplantation.2 Approximately 3%(170 million) of the worlds population has been infected with HCV.